Botanix Pharmaceuticals Ltd

Botanix Pharmaceuticals is a dermatology company developing novel treatments for common skin diseases and infections | $BOT

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOTZ #ASX #dermatology #pharmaceuticals#pharma #biotech#innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT released Q3 Quarterly Reports. Total prescriptions shipped continued on an upward trajectory, with March the highest-shipment month for Sofdra® (sofpironium).

View the reports here: https://t.co/TykdWxS6ZS

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

REGISTER NOW | Join company executives for our Quarterly Activity and 4C Quarterly Cash Flow Webinar on 29 April at 10.30 am AEST / 8.30 am AWST for an important update.

Click to pre-register: https://t.co/Z3T1lEodNs

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT released Q2 Quarterly Reports. Compared to Q1, total prescriptions for Sofdra® grew 24% to 25,351, and net revenue increased 28% to $9.1 million.
Read the reports here: https://t.co/DVh90bArj3
$BOT #ASX #dermatology #pharmaceuticals#pharma #biotech#innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

📆 REGISTER NOW | Join company executives for our Quarterly Activity and 4C Quarterly Cash Flow Webinar on 27 January at 10.30 am AEDT / 7.30 am AWST for an important update.

Click to pre-register: https://t.co/CXJFoHr27F

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT #ASX #dermatology #pharmaceuticals#pharma #biotech#innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT thanks valued shareholders and other significant contributors to the success of Sofdra(sofpironium) in the Chairman’s Address presented at the Annual General Meeting.

View ASX Release: https://t.co/PSftTnabHs

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT #ASX #dermatology #pharmaceuticals#pharma #biotech#innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT Three Sofdrascientific posters were accepted and exhibited at dermatology continuing medical education (CME) conferences. CME is a trusted source for dermatologists.

Read the full story: https://t.co/8QYqGtSclK

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT #ASX #dermatology #pharmaceuticals#pharma #biotech#innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT This Hyperhidrosis Awareness Month, Botanix will introduce new materials in dermatology offices to raise awareness of excessive underarm sweating and Sofdra® (sofpironium).

Click to read the full story: https://t.co/XOHFNr1vYO

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT CEO Dr Howie McKibbon will present at today’s Canaccord Drug and Device Conference in Noosa, followed by an investor roadshow hosted by Canaccord.
View ASX Release: https://t.co/fC36vyIc7i

$BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT released their Quarterly Reports for Q1 FY2026. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) grew 50% as operating cash outflows dropped by 54%. Net revenue was $7.1m. View Reports: https://t.co/bLRW6Lzlta
#dermatology #pharmaceuticals #pharma #biotech

[Botanix Pharmaceuticals Ltd @BotanixPharma]

REGISTER NOW | Join company executives for our Quarterly Activity and 4C Quarterly Cash Flow Webinar, Monday 20 October at 11.00 am AEDT / 8.00 am AWST for an important update. Pre-register: https://t.co/cyLT8GFNhc $BOT #dermatology #pharma #biotech #innovation #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

Executive Chairman Vince Ippolito will present on behalf of Botanix at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US) on 9 September at 2–2.30 am AEST. View ASX Release & Presentation: https://t.co/j2TAfMTDTs
$BOT #ASX #dermatology #hyperhidrosis

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million in cash and $15.3 million in undrawn debt. Operating costs are stable, and revenue is expected to increase quarterly. Botanix is well funded to achieve profitability. https://t.co/fMQXHMeuPG

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT welcomes Dr Patricia Walker to the Board. She brings experience on boards of leading dermatology companies and a working dermatologist's insights. She led drug development for many key dermatology products, including Sofdra™ (sofpironium). https://t.co/nrhAxiA9yu

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT CEO Dr Howie McKibbon will present at the Canaccord Genuity Annual Growth Conference, which attracts institutional investors and features promising global growth companies, including those in healthcare. View Release https://t.co/95Hq9ad2hn #ASX #dermatology #hyperhidrosis